Value
7.9/10data confidence 83%| Component | Sub-score |
|---|---|
| P/S | 10.0 |
| EV/EBITDA | 9.4 |
| Fwd P/E | 4.1 |
| PEG | 10.0 |
| Analyst target | 6.0 |
- ▸Forward P/E: 29.7x
- ▸PEG: 0.40
- ▸Attractively valued
TAK · Why this verdict
Why Takeda Pharmaceutical Company L (TAK) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Takeda Pharmaceutical trades at an attractively valued forward price-to-earnings of 29.8x for a global pharma with 186% free cash flow conversion and 31% analyst upside, but three consecutive earnings misses and weak revenue growth signal the business has not yet demonstrated the execution quality needed to close the valuation gap.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Free cash flow is 186% of net income, indicating Takeda converts every dollar of reported profit into nearly two dollars of actual cash, a hallmark of a capital-light pharmaceutical business with strong intellectual property revenue streams. Quality breakdown | Free cash flow conversion remains above 150% of net income over the next four reported quarters, sustaining the dividend and debt reduction capacity. | →Stable |
| CounterHigh FCF relative to earnings can reflect aggressive non-cash charges or amortization of acquired assets rather than genuine operational superiority; for a company with three earnings misses, the quality is harder to trust. | ||
Analysts have a consensus target implying 31% upside from the current price of $15.77, with the take-profit level at $17.57 representing an 11.4% return, and analyst sentiment scores of 6.82 average rating with a 3x reward-to-risk ratio. Sentiment breakdown | The stock reaches at least $17.57 within 12 months, representing the near-term analyst target and confirming the upside case is achievable. | →Stable |
| CounterAnalyst upside targets for international pharma names with earnings miss records frequently overestimate recovery speed; the gap between the target and current price may narrow through target cuts rather than price appreciation. | ||
Three consecutive earnings misses with large negative surprises of negative 105%, negative 43%, and negative 70% indicate that Takeda has systematically overestimated its own earnings power over multiple planning cycles. Earnings | The company beats consensus EPS estimates in at least 2 of the next 4 quarters and average surprise rises above 0%, demonstrating that guidance calibration has improved. | →Stable |
| CounterThe data covers periods including 2021-2023 which may reflect extraordinary charges from prior acquisitions; the most recent available beat of 54% in July 2023 suggests the miss pattern may have already turned. | ||
News sentiment is positive at plus 0.53 and the value score of 7.0 reflects a genuine discount to peers on multiple metrics including price-to-earnings, price-to-sales, and EV/EBITDA, providing a fundamental floor for the stock. Valuation breakdown | The forward price-to-earnings multiple expands from 29.8x to at least 33x over 12 months as earnings stabilize and the positive news sentiment catalyzes re-rating. | →Stable |
| CounterA 29.8x forward price-to-earnings is not cheap for a pharma company with no revenue growth and below-average quality scores; the valuation discount to comparable western pharma names may be deserved given governance and pipeline concerns. | ||
Free cash flow is 186% of net income, indicating Takeda converts every dollar of reported profit into nearly two dollars of actual cash, a hallmark of a capital-light pharmaceutical business with strong intellectual property revenue streams.
→StableQuality breakdown
- Expectation
- Free cash flow conversion remains above 150% of net income over the next four reported quarters, sustaining the dividend and debt reduction capacity.
CounterHigh FCF relative to earnings can reflect aggressive non-cash charges or amortization of acquired assets rather than genuine operational superiority; for a company with three earnings misses, the quality is harder to trust.
Analysts have a consensus target implying 31% upside from the current price of $15.77, with the take-profit level at $17.57 representing an 11.4% return, and analyst sentiment scores of 6.82 average rating with a 3x reward-to-risk ratio.
→StableSentiment breakdown
- Expectation
- The stock reaches at least $17.57 within 12 months, representing the near-term analyst target and confirming the upside case is achievable.
CounterAnalyst upside targets for international pharma names with earnings miss records frequently overestimate recovery speed; the gap between the target and current price may narrow through target cuts rather than price appreciation.
Three consecutive earnings misses with large negative surprises of negative 105%, negative 43%, and negative 70% indicate that Takeda has systematically overestimated its own earnings power over multiple planning cycles.
→StableEarnings
- Expectation
- The company beats consensus EPS estimates in at least 2 of the next 4 quarters and average surprise rises above 0%, demonstrating that guidance calibration has improved.
CounterThe data covers periods including 2021-2023 which may reflect extraordinary charges from prior acquisitions; the most recent available beat of 54% in July 2023 suggests the miss pattern may have already turned.
News sentiment is positive at plus 0.53 and the value score of 7.0 reflects a genuine discount to peers on multiple metrics including price-to-earnings, price-to-sales, and EV/EBITDA, providing a fundamental floor for the stock.
→StableValuation breakdown
- Expectation
- The forward price-to-earnings multiple expands from 29.8x to at least 33x over 12 months as earnings stabilize and the positive news sentiment catalyzes re-rating.
CounterA 29.8x forward price-to-earnings is not cheap for a pharma company with no revenue growth and below-average quality scores; the valuation discount to comparable western pharma names may be deserved given governance and pipeline concerns.
Per-dimension breakdown
Quality
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 1.7 |
| Gross margin | 8.8 |
| Op margin | 4.4 |
| Net margin | 0.0 |
| Current ratio | 4.3 |
| FCF quality | 7.0 |
| Moat | 5.4 |
| Piotroski F | 8.9 |
- ▸FCF-positive despite GAAP loss (FCF margin 15%, FCF yield 1354.5%)
- ▸No competitive moat
- ▸Strong Piotroski F-Score: 8/9
Growth
3.5/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 3.5 |
Momentum
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 7.1 |
| OBV | 1.0 |
| MA position | 5.2 |
| Volume | 0.0 |
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA but MA still rising (+1.3%/30d) — pullback in uptrend, not confirmed weakness
Sentiment
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.4 |
| Analyst rating | 6.8 |
| Price target | 8.7 |
- ▸Light analyst coverage (3.0) — signal dampened
- ▸Analyst upside: 32%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
4.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 9.6 |
| quality rank | 2.5 |
| growth rank | 4.4 |
Technical
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.9 |
| support resistance | 4.3 |
| 52w position | 6.6 |
Risk (lower is worse)
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 9.9 |
| days to cover | 9.4 |
| volatility | 8.6 |
| put call | 6.5 |
| implied vol | 6.9 |
| max pain risk | 3.0 |
| beta | 10.0 |
| debt equity | 6.6 |
- ▸Above max pain $2
Catalyst
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 6.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| dividend safety | 3.5 |
| news activity | 7.0 |
- ▸Earnings concerns: 1B/3M
- ▸Yield trap warning: high yield but unsafe
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (6)
- ASYMMETRY:2.3>=1.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:35d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:3.6<4.5
Warning (0)
none
Reward-to-Risk
2.30
Upside
+11.8%
Downside
5.1%
Sizing output
AVOID
SetupRANGE_BOUND — RSI 55 mid-range, Bollinger mid-band
EdgeNO_EDGE — No clear edge identified
SuitabilityMODERATE — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 5.2 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Value at 7.9) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( MOMENTUM:3.6<4.5) reinforce the read. Current asymmetry R:R is 2.30 — supplementary context, not the trigger for this path.
The strongest dimensions are Value at 7.9, Risk (lower is worse) at 7.6, and Sentiment at 7.2; the weakest are Growth at 3.5, Catalyst at 3.6, and Momentum at 3.6. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 2.30 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Free cash flow is 186% of net income, indicating Takeda converts every dollar of reported profit into nearly two dollars of actual cash, a hallmark of a capital-light pharmaceutical business with strong intellectual property revenue streams.
Trip ifFree cash flow conversion falls below 100% of net income in at least 2 of the next 4 reported quarters, indicating the cash generation advantage has deteriorated.
- P2Analysts have a consensus target implying 31% upside from the current price of $15.77, with the take-profit level at $17.57 representing an 11.4% return, and analyst sentiment scores of 6.82 average rating with a 3x reward-to-risk ratio.
Trip ifAnalyst consensus price target falls below $14, representing a downward revision of more than 10% from the current implied near-term target of $17.57.
- P3Three consecutive earnings misses with large negative surprises of negative 105%, negative 43%, and negative 70% indicate that Takeda has systematically overestimated its own earnings power over multiple planning cycles.
Trip ifEPS surprise falls below 0% in at least 3 of the next 4 quarterly reports, confirming that the systematic miss pattern has not improved.
- P4News sentiment is positive at plus 0.53 and the value score of 7.0 reflects a genuine discount to peers on multiple metrics including price-to-earnings, price-to-sales, and EV/EBITDA, providing a fundamental floor for the stock.
Trip ifForward price-to-earnings falls below 25x without a corresponding improvement in revenue growth above 5%, indicating the multiple has compressed rather than expanded.